|
Active substance |
palbociclib |
|
Holder |
Pfizer |
|
Status |
Closed |
|
Indication |
patients suffering from advanced/metastatic breast cancer hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative with endocrine therapy |
|
Public documents |
|
|
Last update |
27/07/2018 |
Ibrance®
Last updated on 10/09/2024